Nemaura Medical (NASDAQ:NMRD) is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) designed to provide persons with diabetes and pre-diabetics with an Ambulatory Glucose Profile (AGP) as a superior metric to better manage their glucose levels as compared to an HbA1c reading. Insulin users can adjunctively use sugarBEAT® when calibrated with a finger-stick glucose reading.
SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five-minute intervals for periods of up to 24 hours.
Please click here to view our Tear Sheet
Please click here to view our Corporate Presentation.
– The global TAM for CGM is estimated at $82Bn per annum, consisting of (i) $12.7Bn for Type I insulin users (5% of diabetics), (ii) $38.0Bn for Type II insulin users (15% of diabetics) and (iii) $31.4Bn for Type II non-insulin users (80% of diabetics).1 These numbers exclude the pre-diabetic population which is estimated at nearly three times as large as the diabetic population.
– CGM currently has low adoption rates amongst insulin users (negligible use amongst non-insulin users) and is growing rapidly. The U.S. is the largest market with estimated 2.6% (630,000 users) penetration of diagnosed diabetic market (24.6M), representing annual growth of 117% over 2017 (290,000 users). 1
– Given sugarBEAT ® is (i) non-invasive, (ii) affordable and (iii) flexible, it is expected to have wider appeal to (i) non-insulin using diabetics, (ii) pre-diabetics and (iii) a section of insulin-users who dislike competitor CGMs owing to their (i) invasiveness, (ii) cost and (iii) inflexibility
1 PiperJaffray Company Note DXCM Sep 5, 2018
NASDAQ:NMRD - Key Points: